What genetic mutations cause beta (beta thalassemia) versus alpha (alpha thalassemia) thalassemia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 5, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Genetic Mutations in Beta vs Alpha Thalassemia

Beta-thalassemia is caused by mutations in the HBB gene on chromosome 11, while alpha-thalassemia is caused by mutations in the alpha-globin genes on chromosome 16.

Beta-Thalassemia Genetic Basis

Beta-thalassemia results from mutations in the HBB gene (hemoglobin subunit beta gene) located on chromosome 11. 1 Humans have only two beta-globin genes (one on each chromosome 11), making the condition particularly impactful even with heterozygous mutations. 1

Types of HBB Mutations

The molecular heterogeneity is extensive, with the following mutation patterns:

  • Point mutations are the most common cause, including single nucleotide substitutions that affect beta-globin synthesis 2, 3
  • Small deletions or insertions leading to frameshift mutations 3
  • Pre-terminating mutations that create premature stop codons (e.g., c.271 G>T creating a stop codon at amino acid 90) 4
  • Gross gene deletions occur rarely 3
  • Over 200 disease-causing mutations have been identified, with more than 350 mutations documented in the β-globin gene 3, 5

Beta-Thalassemia Phenotypes

The severity depends on the specific mutation type:

  • β⁰ mutations result in complete absence of beta-globin chain production 6
  • β⁺ mutations cause reduced but not absent beta-globin production 7
  • The clinical severity correlates with the extent of imbalance between alpha and non-alpha globin chains 3

Inheritance Pattern

Beta-thalassemia follows an autosomal recessive inheritance pattern:

  • Heterozygous mutations (beta-thalassemia trait) cause detectable hematologic changes with persistent microcytic anemia 1, 5
  • Homozygosity or compound heterozygosity results in thalassemia major, requiring lifelong transfusions 7, 1
  • When two carriers reproduce, there is a 25% chance of thalassemia major and 50% chance of carrier offspring 5

Alpha-Thalassemia Genetic Basis

While the provided evidence focuses primarily on beta-thalassemia, the fundamental distinction is clear: alpha-thalassemia is caused by mutations or deletions in the alpha-globin gene cluster on chromosome 16 (general medical knowledge, as specific evidence for alpha-thalassemia genetics was not provided in the references).

Key Genetic Differences

The critical distinction between these conditions:

  • Beta-thalassemia: HBB gene on chromosome 11 (predominantly point mutations) 1, 3
  • Alpha-thalassemia: Alpha-globin genes on chromosome 16 (predominantly gene deletions)
  • Humans have two beta-globin genes but four alpha-globin genes (two on each chromosome 16), making alpha-thalassemia phenotypically variable depending on how many genes are affected

Clinical Implications of Genetic Differences

Timing of Presentation

Infants with beta-thalassemia are healthy at birth because fetal hemoglobin (HbF) does not require beta-globin chains. 7, 1 Symptoms emerge at 1-2 years of age as the switch from fetal to adult hemoglobin occurs. 7, 1

Diagnostic Approach

Both conditions present with microcytic hypochromic anemia, but genetic testing confirms the specific diagnosis:

  • MCV typically <80 fL in both conditions 1
  • Hemoglobin electrophoresis shows elevated HbA2 (>4.0%) in beta-thalassemia trait 5
  • Genetic testing definitively distinguishes beta from alpha thalassemia 1

Common Pitfall

Do not prescribe iron supplementation to patients with confirmed thalassemia trait—it provides no benefit and may contribute to unnecessary iron accumulation. 1 Always check serum ferritin to rule out concurrent iron deficiency before attributing microcytic anemia solely to thalassemia trait. 1

References

Guideline

Thalassemia Diagnosis and Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Research

Beta-thalassemia.

Genetics in medicine : official journal of the American College of Medical Genetics, 2010

Research

Identification of a novel pre-terminating mutation in human HBB gene as a cause of β0-thalassemia phenotype.

International journal of clinical and experimental pathology, 2019

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Etiopathogenesis and Clinical Manifestations of Thalassemia Major

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Related Questions

What is the recommended management and counseling approach for individuals with alpha thalassemia trait?
What are the diagnosis and treatment options for a patient with beta thalassemia?
What is the management approach for patients with beta thalassemia minor?
What are the key differences in management and health implications between beta thalassemia minor (beta thalassemia trait) and alpha thalassemia minor (alpha thalassemia trait)?
What is the management approach for alpha thalassemia in Albanian individuals?
What are the considerations for using Caplyta (lumateperone) with lamotrigine in a patient with bipolar disorder (BPD)?
What is the classification, diagnosis, and prognosis of Acute Myeloid Leukemia (AML) in adults, particularly those over 60 years old with a history of myelodysplastic syndromes, radiation exposure, or previous chemotherapy?
What is the appropriate course of action for a 1 year 2 month old child with leukocoria, a non-reactive pupil, and an irregular lesion in the right eye, accompanied by exotropia and an absence of a visible fundus, while the left eye appears normal with a reactive pupil and visible fundus?
Can a patient with severe renal impairment and a need for tighter glycemic control start on insulin (12 units once daily) and dapagliflozin (10 mg daily), with the removal of gliclazide?
What is the best management approach for a patient with right lower back pain in the L4, L5 area and midline pain, with a negative straight leg raise test?
What is a suitable dose of lithium to augment 200 mg of lamotrigine (lamotrigine) in an adult patient with bipolar disorder and no significant impaired renal function (renal impairment)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.